沙库巴曲缬沙坦钠治疗射血分数保留的心力衰竭患者临床观察OACSTPCD

Objective To investigate the clinical efficacy of sacubitril valsartan sodium in the treatment of patients with heart failure with preserved ejection fraction(HFpEF),and its effect on serum soluble intercellular adhesion molecule-1(sICAM-1),endothelin-1(ET-1),and nitric oxide(NO)levels in patients.Methods A total of 112 patients with HFpEF admitted to the hospital from January 2020 to June 2022 were selected and divided into the observation group and the control group according to different treatment methods,with 56 cases in each group.All patients were given routine treatments such as β-receptor blockers and spironolactone,on this basis,the patients in the control group and the observation group were treated with Benazepril Hydrochloride Tablets and Sacubitril Valsartan Sodium Tablets,respectively.Both groups were treated for six months.Results The total effective rate in the observation group was 91.07%,which was higher than 76.79%in the control group(P＜0.05).After treatment,the 6-minute walking distance,left ventricular ejection fraction,A-peak to E-peak flow velocity ratio,and serum NO level in the observation group were significantly higher than those in the control group(P＜0.05),while the levels of serum sICAM-1 and ET-1 in the observation group were significantly lower than those in the control group(P＜0.05).The readmission rate in the observation group within six months was 5.36%,which was significantly lower than 17.86%in the control group(P＜0.05).During the treatment period,the incidence of adverse reactions in the observation group was comparable to that in the control group(21.43%vs.12.50%,P＞0.05).Conclusion Sacubitril valsartan sodium in the treatment of patients with HFpEF has good clinical efficacy and safety,which can improve cardiac function,regulate serum levels of sICAM-1,ET-1,NO expression levels,alleviate clinical symptoms of heart failure,and reduce readmission rate.